China-based CanSino Biologics Inc. (HKG: 6185) has entered into a collaboration agreement with Saudi pharmaceutical firm SPIMACO, a leader in the Middle East and North Africa (MENA) region. The partnership aims to enhance access to CanSino’s ACYW135 Meningococcal Conjugate Vaccine (CRM197) (MCV4, trade name: Menhycia) in Saudi Arabia and other EMNA markets. The collaboration also focuses on joint research and development and the construction of localized manufacturing systems.
Vaccine Demand and Features
The quadrivalent meningococcal conjugate vaccine has been incorporated into Saudi Arabia’s childhood immunization program, where there is a pressing need for vaccines offering longer-lasting and safer immune protection. Menhycia stimulates immunity against ACYW135 Neisseria meningitidis and is approved for use in individuals aged 3 months to 6 years. It carries advanced carrier proteins, ensuring good safety, tolerability, and immunogenicity.
Market Strategy and Previous Collaboration
CanSino previously partnered with Pfizer in July 2020 for academic promotion of Menhycia in mainland China. However, this collaboration was terminated in June 2022. Since then, CanSino has taken charge of the domestic and international market strategies, as well as the planning and execution of marketing activities for Menhycia.-Fineline Info & Tech
Leave a Reply